|
Real-time Estimate
Cboe BZX
12:08:49 2026-10-20 pm EDT
|
5-day change | 1st Jan Change | ||
| 509.52 USD | +1.51% |
|
+5.37% | +12.78% |
| Oct. 15 | Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 | MT |
| Oct. 09 | Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children | MT |
| Market Cap | 127B 113B 105B 95.52B 179B 12,062B 182B 1,260B 495B 6,304B 477B 467B 20,153B | P/E 2026 * |
33.5x | P/E 2027 * | 27x |
|---|---|---|---|---|---|
| Enterprise Value | 120B 107B 99.31B 90.29B 169B 11,402B 172B 1,191B 468B 5,959B 451B 442B 19,051B | EV / Sales 2026 * |
9.06x | EV / Sales 2027 * | 8.08x |
| Free-Float |
99.79% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VRTX | Delayed | |
CBOE
| VRTX | Real-time | |
|
Mexican S.E.
| VRTX * | End-of-day quote | |
|
Tradegate
| VX1 | Real-time | |
|
Boerse Muenchen
| VX1 | Real-time | |
|
Borsa Italiana
| 1VRTX | End-of-day quote | |
|
Xetra
| VX1 | Delayed | |
|
London S.E.
| 0QZU | Delayed | |
|
Börse Stuttgart
| VX1 | Delayed | |
|
Deutsche Boerse AG
| VX1 | Delayed | |
|
Wiener Boerse
| VRTX | End-of-day quote | |
|
CBOE
| 0QZU | Real-time | |
|
CBOE
| Real-time |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | +1.91% | ||
| 1 week | +5.37% | ||
| Current month | -2.20% | ||
| 1 month | +0.11% | ||
| 3 months | +6.41% | ||
| 6 months | +16.42% | ||
| Current year | +12.78% |
| 1 week | 487.54 |  | 517.68 |
| 1 month | 484.08 | | 529.89 |
| Current year | 412.27 | | 560.25 |
| 1 year | 403.16 | | 560.25 |
| 3 years | 341.9 | | 560.25 |
| 5 years | 179.96 | | 560.25 |
| 10 years | 71.46 | | 560.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 2020-03-31 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 2019-04-09 |
Sean Daughtry
CTO | Chief Tech/Sci/R&D Officer | - | 2024-02-29 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 1997-12-31 |
Jeffrey Leiden
CHM | Chairman | 70 | 2012-04-30 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 2015-06-17 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/28/26 | Free | Controller/Auditor | 5,000 | 0.0020% | ||
| 8/27/26 | Don | Director | -6,000 | 0.0024% | ||
| 7/21/26 | Free | General Counsel | 8,251 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.84% | +5.37% | +22.00% | +41.29% | 127B | |
| +4.47% | +11.55% | +60.85% | +122.57% | 1,106B | |
| +2.15% | +4.22% | +33.75% | +69.35% | 612B | |
| +2.02% | +4.88% | +23.99% | +96.77% | 500B | |
| +2.35% | +8.17% | +38.46% | +62.85% | 367B | |
| +2.96% | +4.28% | +71.52% | +44.20% | 354B | |
| +1.60% | +5.45% | +20.80% | +48.35% | 286B | |
| +1.55% | +5.36% | -0.24% | +20.17% | 256B | |
| +2.20% | +5.32% | +43.34% | +55.94% | 230B | |
| +1.71% | +4.93% | +26.07% | +99.50% | 190B | |
| Average | +2.24% | +5.95% | +34.05% | +66.10% | 402.74B | |
| Weighted average by Cap. | +2.78% | +6.97% | +40.47% | +79.71% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.27B 11.83B 10.96B 9.96B 18.69B 1,258B 19B 131B 51.68B 657B 49.78B 48.74B 2,102B | 14.56B 12.98B 12.03B 10.94B 20.52B 1,381B 20.86B 144B 56.72B 722B 54.65B 53.5B 2,307B |
| Net income | 3.88B 3.46B 3.21B 2.92B 5.47B 368B 5.56B 38.47B 15.13B 192B 14.57B 14.27B 615B | 4.89B 4.36B 4.04B 3.67B 6.89B 463B 7B 48.41B 19.03B 242B 18.34B 17.95B 774B |
| Net Debt | -6.96B -6.2B -5.75B -5.22B -9.8B -660B -9.97B -68.93B -27.1B -345B -26.11B -25.56B -1,102B | -9.58B -8.54B -7.91B -7.19B -13.5B -908B -13.72B -94.9B -37.32B -475B -35.95B -35.2B -1,518B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-20 | $511.10 | +1.82% | 323,268 |
| 26-10-19 | $501.95 | +0.44% | 1,298,739 |
| 26-10-16 | $499.74 | -1.77% | 1,413,287 |
| 26-10-15 | $508.75 | +2.06% | 2,262,588 |
| 26-10-14 | $498.50 | +2.74% | 2,090,487 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
